- Investing Ideas
- /
- Retail Healthcare Sector
Retail Healthcare Sector
Results
2309
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
2,309 companies
iCAD
Market Cap: US$108.4m
Provides AI-powered cancer detection solutions in the United States.
ICAD
US$3.99
7D
10.8%
1Y
128.0%
Lexeo Therapeutics
Market Cap: US$107.5m
A clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
LXEO
US$3.24
7D
20.4%
1Y
-76.6%
Achieve Life Sciences
Market Cap: US$106.8m
A clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction.
ACHV
US$3.08
7D
31.1%
1Y
-38.4%
Kewaunee Scientific
Market Cap: US$106.5m
Designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products.
KEQU
US$37.31
7D
7.0%
1Y
-3.7%
Lineage Cell Therapeutics
Market Cap: US$105.7m
A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
LCTX
US$0.46
7D
5.2%
1Y
-57.1%
Imugene
Market Cap: AU$164.3m
A clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
IMU
AU$0.022
7D
0%
1Y
-69.4%
ALT5 Sigma
Market Cap: US$104.8m
Provides blockchain-powered technologies worldwide.
ALTS
US$6.80
7D
11.5%
1Y
100.6%
Entasis Therapeutics Holdings
Market Cap: US$104.8m
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States.
ETTX
US$2.19
7D
0%
1Y
-14.8%
ProKidney
Market Cap: US$104.5m
A clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.
PROK
US$0.81
7D
11.8%
1Y
-80.1%
Nautilus Biotechnology
Market Cap: US$103.9m
A development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
NAUT
US$0.82
7D
17.7%
1Y
-72.1%
Sagimet Biosciences
Market Cap: US$103.7m
A clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.
SGMT
US$3.22
7D
-1.2%
1Y
-30.3%
MDxHealth
Market Cap: US$103.4m
A commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
MDXH
US$2.09
7D
11.8%
1Y
-27.4%
Cabaletta Bio
Market Cap: US$103.0m
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
CABA
US$2.03
7D
70.6%
1Y
-83.6%
Agape ATP
Market Cap: US$102.5m
An investment holding company, supplies health and wellness products and health solution advisory services in Malaysia.
ATPC
US$2.05
7D
31.4%
1Y
-59.8%
Assembly Biosciences
Market Cap: US$102.5m
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
ASMB
US$13.42
7D
9.6%
1Y
-7.6%
Cardiff Lexington
Market Cap: US$101.1m
Operates in the health care industry in the United States.
CDIX
US$6.50
7D
0%
1Y
-7.1%
Cassava Sciences
Market Cap: US$101.0m
A clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
SAVA
US$2.09
7D
18.1%
1Y
-91.0%
Kyverna Therapeutics
Market Cap: US$100.3m
Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
KYTX
US$2.32
7D
10.0%
1Y
-85.0%
MacroGenics
Market Cap: US$99.7m
A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.
MGNX
US$1.58
7D
10.5%
1Y
-63.8%
Ventyx Biosciences
Market Cap: US$99.6m
A clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.
VTYX
US$1.40
7D
12.9%
1Y
-70.4%
Coya Therapeutics
Market Cap: US$99.2m
A clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs).
COYA
US$5.93
7D
-2.0%
1Y
-32.1%
OptiNose
Market Cap: US$98.1m
A specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists.
OPTN
US$9.69
7D
3.2%
1Y
-48.7%
C4 Therapeutics
Market Cap: US$98.0m
A clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
CCCC
US$1.38
7D
-6.1%
1Y
-75.7%
HilleVax
Market Cap: US$97.7m
A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.
HLVX
US$1.97
7D
3.7%
1Y
-87.6%
Microbot Medical
Market Cap: US$97.2m
A clinical-stage medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space in Israel and the United States.
MBOT
US$2.68
7D
6.3%
1Y
185.1%
Aroa Biosurgery
Market Cap: AU$151.8m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.44
7D
-4.3%
1Y
-11.1%
EMVision Medical Devices
Market Cap: AU$151.4m
Engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia.
EMV
AU$1.77
7D
-7.3%
1Y
-6.8%
BioSyent
Market Cap: CA$134.8m
Acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.
RX
CA$11.75
7D
8.3%
1Y
30.6%
Cuprina Holdings (Cayman)
Market Cap: US$96.1m
A biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds.
CUPR
US$4.48
7D
-7.6%
1Y
n/a
Instil Bio
Market Cap: US$95.5m
A clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.
TIL
US$14.63
7D
10.6%
1Y
27.2%
Agenus
Market Cap: US$95.4m
A clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally.
AGEN
US$3.48
7D
19.6%
1Y
-68.0%
Invivyd
Market Cap: US$93.2m
A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
IVVD
US$0.78
7D
20.2%
1Y
-67.6%
RetinalGenix Technologies
Market Cap: US$93.0m
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders.
RTGN
US$5.02
7D
0%
1Y
n/a
XBiotech
Market Cap: US$92.7m
A biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases.
XBIT
US$3.04
7D
9.7%
1Y
-63.9%
Genelux
Market Cap: US$92.5m
A clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
GNLX
US$2.48
7D
-16.2%
1Y
-32.1%
Xtant Medical Holdings
Market Cap: US$92.3m
Provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally.
XTNT
US$0.66
7D
31.3%
1Y
-8.0%